Re­gen­eron touts pos­i­tive pre­lim­i­nary im­pact of its Covid an­ti­body cock­tail, pre­vent­ing symp­to­matic in­fec­tions in high-risk group

Re­gen­eron flipped its cards on an in­ter­im analy­sis of the da­ta be­ing col­lect­ed for its Covid-19 an­ti­body cock­tail used as a safe­guard against ex­po­sure to the virus. And the re­sults are dis­tinct­ly pos­i­tive.

The big biotech re­port­ed Tues­day morn­ing that their casiriv­imab and imde­vimab com­bo pre­vent­ed any symp­to­matic in­fec­tions from oc­cur­ring in a group of 186 peo­ple ex­posed to the virus through a fam­i­ly con­nec­tion, while the place­bo arm saw 8 of 223 peo­ple ex­pe­ri­ence symp­to­matic in­fec­tion. Symp­to­matic com­bined with asymp­to­matic in­fec­tions oc­curred in 23 peo­ple among the 223 place­bo pa­tients com­pared to 10 of the 186 sub­jects in the cock­tail arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER